Hytrin

Terazosin, the active ingredient in Hytrin, is a Alpha-1 adrenergic antagonist presented as a tablet for oral use. It treats hypertension and benign prostatic hyperplasia in adults. GNH USA supplies Hytrin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Terazosin is indicated for conditions involving the cardiovascular system and the prostate where alpha‑1 adrenergic blockade is beneficial.

- Hypertension: lowers blood pressure by reducing peripheral vascular resistance. - Benign prostatic hyperplasia (BPH): relaxes prostatic smooth muscle to improve urinary flow. - Elevated systolic blood pressure: assists in achieving target blood‑pressure goals in patients with essential hypertension.

Common Side Effects: - Dizziness or light‑headedness, especially on standing. - Headache. - Fatigue or general weakness. - Nasal congestion or runny nose. - Peripheral edema. - Orthostatic hypotension.

Serious or Rare Side Effects: - Severe hypotension leading to syncope. - Priapism (prolonged penile erection). - Allergic reactions such as rash, itching, or angioedema. - Hepatic dysfunction indicated by jaundice or abnormal liver enzymes. - Cardiac arrhythmias in susceptible patients. - Acute renal failure in the setting of severe hypotension.

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly, especially during dose titration. - Assess for orthostatic hypotension; advise patients to rise slowly. - Review renal and hepatic function; adjust dose if impairment is present. - Avoid abrupt discontinuation to prevent rebound hypertension. - Use caution in patients with a history of cardiovascular disease or heart failure. - Store at ambient temperature: keep in the original pack, protect from moisture.

Terazosin may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Concurrent use with other potent antihypertensives (e.g., ACE inhibitors, other alpha‑blockers) can cause additive hypotension. - PDE5 inhibitors such as sildenafil may precipitate severe blood‑pressure drops. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase terazosin plasma levels.

Moderate Interactions (Monitor Closely):\n- Diuretics may enhance orthostatic effects; monitor volume status. - NSAIDs can blunt the antihypertensive response. - Lithium therapy may result in elevated lithium concentrations; check serum levels.